Skip to main content
Atrás
Watch Compare

Transcode Therapeutics, Inc.

Calidad de datos: 83%
RNAZ
Nasdaq Manufacturing Chemicals
$8.57
▲ $0.21 (2.49%)
Cap. Mercado: 7.86 M
Precio
$8.57
Cap. Mercado
7.86 M
Rango del Día
$8.22 — $8.57
Rango de 52 Semanas
$6.08 — $22.04
Volumen
2,829
Apertura $8.30
Promedio 50D / 200D
$9.59
10.62% below
Promedio 50D / 200D
$9.89
13.39% below

Quick Summary

Puntos Clave

Negative free cash flow of -14.54 M

Crecimiento

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Calidad

Return on Equity
-716.53%
Below sector avg (-51.02%)
ROIC-300.58%
Net MarginN/A
Op. MarginN/A

Seguridad

Debt / Equity
N/A
Current Ratio1.60
Interest Coverage-2156.07

Valoración

PE (TTM)
-0.29
Above sector avg (-1.98)
P/B Ratio5.51
EV/EBITDAN/A
Dividend YieldN/A

Historial de Precios

Tendencias Financieras

Comparación con Pares

vs mediana del sector Manufacturing (44 pares)
Métrica Acción Mediana del Sector
P/E -0.3 -2.0
P/B 5.5 5.1
ROE % -716.5 -51.0
Net Margin % — -150.2
Rev Growth 5Y % — 9.3
D/E — 0.3

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -27.13 M
ROE -716.53% ROA -402.19%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -14.54 M
ROIC -300.58% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 1.60
Interest Coverage -2156.07 Asset Turnover N/A
Working Capital 1.78 M Tangible Book Value 1.43 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0.29 Forward P/E N/A
P/B Ratio 5.51 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -185.09%
Market Cap 7.86 M Enterprise Value 5.02 M
Per Share
EPS (Diluted TTM) -80.42 Revenue / Share N/A
FCF / Share -15.86 OCF / Share -15.83
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 53.59%
SBC-Adj. FCF -16.29 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021
Revenue — — — —
Net Income -16.75 M -18.55 M -17.56 M -6.84 M
EPS (Diluted) -47.14 -103.61 -1.35 -0.81
Gross Profit — — — —
Operating Income -15.66 M -19.42 M -18.67 M -6.15 M
EBITDA — — — —
R&D Expenses 9.71 M 12.26 M 10.23 M 2.75 M
SG&A Expenses — — — —
D&A 90,894.0 123,483.0 98,606.0 42,470.0
Interest Expense 26,813.0 55,899.0 95,070.0 95,070.0
Income Tax 0.0 0.0 0.0 53,051.0

Balance Sheet

Annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021
Total Assets 7.29 M 5.17 M 7.59 M 22.94 M
Total Liabilities 9.31 M 3.53 M 4.35 M 2.53 M
Shareholders' Equity -2.02 M 1.64 M 3.24 M 20.40 M
Total Debt — — — —
Cash & Equivalents 5.81 M 2.77 M 4.97 M 20.83 M
Current Assets 7.09 M 4.46 M 7.38 M 22.73 M
Current Liabilities 2.77 M 3.49 M 4.35 M 2.53 M